Leela Barham Economic Consulting

Please email me if you would like copies of my publications.

Healthcare and Pharmaceuticals

Research contribution to Smith, S. et al., 2012. Urbanization and cardiovascular disease: Raising heart-healthy children in today’s cities. [pdf] Geneva: The World Heart Federation http://www.world-heart-federation.org/fileadmin/user_upload/images/Publications/FinalWHFUrbanizationLoResWeb.pdf

L Barham, Economic Crisis: Consequences for Patients, Chronic Pain Clinics, and the Pharmaceutical Industry Journal of Pain and Palliative Care Pharmacotherapy

2011, Vol. 25, No. 4 , Pages 382-385

L Barham, Payer Agreements: Splitting the Risk, First Word, October 2011 http://www.firstwordplus.com/payer_agreements_splitting_the_risk.do

L Barham, EUnetHTA Joint Action: Past, Present and Future, Pharma Pricing and Reimbursement (December 2011) Vol 16 No 12 356-357

L Barham, Market access: how to engage emerging stakeholders, 6th November 2011, http://social.eyeforpharma.com/market-access/market-access-how-engage-emerging-stakeholders

L Barham and S Bevan, The place of work in health care decision making, October 2011 http://blog.fitforworkeurope.eu/2011/10/21/new-ffw-thought-piece-on-the-place-of-work-in-healthcare-decision-making/

L Barham, Health Technology Assessment: A European Perspective, First Word, September 2011 http://www.firstwordplus.com/health_technology_assessment_a_european_perspective.do

L Barham, Economic burden of chronic pain across Europe, paineurope 2011; 3: 4-5

L Barham, UK: Ongoing debate over proposed off-label use of avastin Pharma Pricing and Reimbursement (July 2011) Vol 16, No 7, 191

L Barham, Economic crisis and pain, paineurope 2011; 2: 8-9

L Barham, Merging market access and launch planning, 25th September 2011 http://social.eyeforpharma.com/market-access/merging-market-access-launch-planning

L Barham, Market access: The impact of HTAs on strategy, 1st September 2011 http://social.eyeforpharma.com/marketing/market-access-impact-htas-strategy

L Barham, The impact of value-based pricing on market access and patient compliance, 2nd August 2011, http://social.eyeforpharma.com/marketing/impact-value-based-pricing-market-access-and-patience-compliance

L Barham, Pharma and the ‘new’ NHS: Getting the most from partnerships 12th July 2011, EyeforPharma http://social.eyeforpharma.com/sales/pharma-and-‘new’-nhs-getting-most-partnerships

L Barham, The ‘new’ NHS: What does it mean for pharma? 13th June 2011, EyeforPharma http://social.eyeforpharma.com/sales/new-nhs-what-does-it-mean-pharma

L Barham, Public and Patient Involvement at the UK National Institute for Health and Clinical Excellence Patient 2011; 4 (1): 1-10

L Barham and N Devlin, Patient reported outcome measures: implications for nursing, Nursing Standard, 2011, 25, 18, 42-45

L Barham, Atrial Fibrillation in Europe: How AWARE are you? A report for SAFE and WHF, November 2010 http://www.world-heart-federation.org/fileadmin/user_upload/documents/AF-Aware/AFAwareReport23nov2010.pdf

L Barham, Joint Early Scientific Advice – Increase Prospects for Market Access? Pharma Pricing and Reimbursement (November 2010) Vol 15, No 11, 335-337

L Barham, Market access: How to meet both marketing authorisation and HTA needs, 13th Jul 2010, EyeforPharma

http://social.eyeforpharma.com/story/market-access-how-meet-both-marketing-authorisation-and-hta-needs

L Barham, UK DoH examines off-label use of Avastin to cut costs, Pharma Pricing and Reimbursement (July 2010), Vol 15, No 7, 190-191

L Barham, Is value-based pricing an aid to market access?, 16th June 2010, EyeforPharma

http://social.eyeforpharma.com/story/value-based-pricing-aid-market-access

L Barham, GSK's approach to corporate social responsibility, 14th June 2010, EyeforPharma

http://social.eyeforpharma.com/story/gsks-approach-corporate-social-responsibility

L Barham, The future of value based pricing in the UK, Pharma Pricing and Reimbursement (June 2010), Vol 15, No 6, 176-177

H Vaughan-Jones and L Barham, Healthy Work: Evidence into Action, (June 2010) Bupa, in association with C3, The Work Foundation, and RAND Europe http://www.bupa.co.uk/about/pdfs/reports/health_at_work.pdf

L Barham, Market access and HTAs: the role of ISPOR, 20th April 2010, EyeforPharma

http://social.eyeforpharma.com/story/market-access-and-htas-role-ispor

L Barham, Use and misuse of the US threshold for cost-effectiveness, Pharma Pricing and Reimbursement (April 2010), Vol 15, No 4, 94

L Barham, Market Access: Insights from the OECD, 23rd March 2010, EyeforPharma

http://social.eyeforpharma.com/story/market-access-insights-oecd

L Barham, UK: Interim results of multiple sclerosis risk sharing scheme, Pharma Pricing and Reimbursement (March 2010) Vol 15, No 3, 63

L Barham, UK consultation on innovation pass pilot, Pharma Pricing and Reimbursement (February 2010) Vol 15, No 2, 36-37

L Barham, Regulators and HTA agencies drawing closer in Europe (February 2010) Vol 15, No 2, 48-49

L Barham, New commissioning support appraisals service in England, Pharma Pricing and Reimbursement (January 2010) Vol 15, No 1, 2-3

L Barham, EC network on HTA, Pharma Pricing and Reimbursement (January 2010) Vol 15, No 1, 20-21

L Barham, Implications of the EC Inquiry into Pharmaceuticals, Pharma Pricing and Reimbursement (November 2009) Vol 14, No 11, 391

L Barham, Financial crisis and health policy: a focus on HTA at Gastein, Pharma Pricing and Reimbursement (November 2009) Vol 14, No 11, 323-333

L Barham, A cold climate for NICE, 01 December 2009, PharmaTimes, http://www.pharmatimes.com/UKNews/article.aspx?id=17007&src=EUKNews

S Bevan, T Quadrello, R McGee, M Mahdon, A Vavrovsky and L Barham Fit for Work? Musculoskeletal Disorders in the European Workforce, The Work Foundation, London (September 2009) http://www.fitforworkeurope.eu/Website-Documents/Fit%20for%20Work%20pan-European%20report.pdf

L Barham UK: Kennedy and OLS Report on State of Innovation Pharma Pricing and Reimbursement (September 2009) Vol 14, No 9, 264-265

L Barham Globalisation in Health Technology Assessment Pharma Pricing and Reimbursement (August 2009) Vol 14, No 8, 244-245

L Barham Happy tenth anniversary NICE Pharma Pricing and Reimbursement (April 2009) Vol 14, No 4, 94

L Barham MS Risk Sharing Update Pharma Pricing and Reimbursement (April 2009) Vol 14, No 4, 95

L Barham NICE: Jury Still Out After 10 Years Pharma Pricing and Reimbursement (April 2009) Vol 14, No 4, 102-104

L Barham NICE is growing up, so too is the SMC Pharma Pricing and Reimbursement (April 2009) Vol 14, No 4, 105-106

L Barham and Peter Mansell Assessing NICE’s expanding role PharmaTimes (April 2009) 27-29

H Vaughan-Jones and L Barham, Healthy Work: Opportunities and Challenges to 2030, (March 2009) Bupa, in association with The Oxford Health Alliance, The Work Foundation, and RAND Europe http://www.bupa.co.uk/about/pdfs/reports/health_at_work.pdf

L Barham EUnetHTA Reports on Three-Year EC Project Pharma Pricing and Reimbursement (February 2009) Vol 14, No 1, 41-43

L Barham Thresholds for Cost Effectiveness– Where to Draw the Line? Pharma Pricing and Reimbursement (January 2009) Vol 14, No 1, 41-43

L Barham, Single Technology Appraisals by NICE Are They Delivering Faster Guidance to the NHS? Pharmacoeconomics 2008; 26 (12): 1037-1043

L Barham, Rationing: A Focus on Europe, Pharma Pricing and Reimbursement (December 2008) Vol 13, No 12, 352-353

L Barham, More Drugs to be Made Available on the NHS but for some patients at their own cost, Pharma Pricing and Reimbursement (December 2008) Vol 13, No 12, 354-357

L Barham, The Impact of Abolishing Co-payments in Wales, Pharma Pricing and Reimbursement (October 2008) Vol 13, No 10, pp294-295

L Barham, Risk-sharing Schemes – The Australian Experience, Pharma Pricing and Reimbursement (October 2008) Vol 13, No 10, pp304-306

L Barham, Time to Top Up, Pharma Pricing and Reimbursement (September 2008) Vol 13, No 9, pp254-255

L Barham, Measuring Access to Medicines – A New Index, Pharma Pricing and Reimbursement (September 2008) Vol 13, No 9, pp 270-271

L Barham, EuroNICE or EuroNASTY? Pharma Pricing and Reimbursement (July 2008) Vol 13, No 7, pp 204-205

L Barham and R Nauman, What Can the US Learn From UK Risk Sharing Pharma Pricing and Reimbursement (May 2008) Vol 13, No 5, pp 136-137

L Barham, Funding Cancer Products – What Are the Options? Pharma Pricing and Reimbursement (April 2008) Vol 13, No.4 p95

L Barham, Defining Risk Sharing Pharma Pricing and Reimbursement (Mar 2008) Vol 13, No 3, pp 78-80

L Barham, Commons Health Committee Delivers Second NICE, Pharma Pricing and Reimbursement (February 2008) Vol 13 No. 2 pp 30-31

L Barham and M Ng (December 2007) Cancer, Health and the Health Service in Wales, for ABPI Wales, NERA, London.

L Barham et al (2007) The Importance of Incentives in Health Care Systems, for International Federation of Pharmaceutical Manufacturers’ Associations (IFPMA) http://www.ifpma.org/Issues/fileadmin/templates/ifpmaissues/pdfs/2007_12_14_NERA-IncentivesReport-Final.pdf

L Barham, Velcade: The Rise of Risk-Sharing in the UK, Pharma Pricing and Reimbursement (September 2007) Vol 12 No. 9 pp 272-273

L Barham, D Lewis and N Latimer (11 July 2007) One to one interventions to reduce sexually transmitted infections and under eighteen conceptions– a systematic review of the economic evaluations, Sexually Transmitted Infections doi:10.1136/sti.2007.025361

http://sti.bmj.com/cgi/content/abstract/sti.2007.025361v1?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&author1=barham&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT

L Barham (March 2007) NICE Tackling Use of Ineffective Technologies – Is More Needed?, Pharma Pricing and Reimbursement Vol 12 No. 3 pp 74-76

L Barham, D Lewis, E Bramley-Harker, S Carter, and A Hanif (2007) The Costs and Benefits of Pre-Screening and Clinical Assessment for Home Oxygen Therapy, for NHS London, NERA, London

http://www.primarycarecontracting.nhs.uk/uploads/HOS/june_2007/appendix_7.pdf

L Barham and E Bramley-Harker (2006) CHD and Diabetes in Wales: Meeting the Challenges, for ABPI Wales, NERA, London

D Lewis and L Barham (2006) Economic Modelling of Interventions to Reduce the Transmission of Chlamydia and Other Sexually Transmitted Infections and to Reduce the Rate of Teenage Conceptions, for National Institute for Health and Clinical Excellence

http://www.nice.org.uk/download.aspx?o=371756

D Lewis, L Barham and N Latimer (2006) Rapid Economic Review of Interventions (Including Screening) to Reduce the Transmission of Chlamydia and other Sexually Transmitted Infections and to Reduce the Rate of Under Eighteen Conceptions, Especially Among Vulnerable and At Risk Groups, for National Institute for Health and Clinical Excellence

http://www.nice.org.uk/download.aspx?o=298584

L Barham (August 2006) Head to Head: NICE and the SMC, PharmaFocus

L Barham (July 2006) Renegotiation of the UK Quality and Outcomes Framework – Focusing on New Clinical Areas, Pharma Pricing and Reimbursement Vol 11 No. 7 pp 202-203

L Barham (April 2006) Multiple Sclerosis Risk-Sharing - Four Years On, Pharma Pricing and Reimbursement Vol 11 No 4 pp100-101

F Barrera, E Bramley-Harker, D Paredes, L Barham, E Canizares and M Ruiz (March 2006) Impacto de la Regulacion Economica Sobre La I+D de La Insustria Farmaceutica Espanola, for Farmaindustria, Madrid, NERA, Madrid

L Barham, E Bramley-Harker and D Lewis (October 2005) Opportunities for Pharma from Choice in Primary Care, PharmaFocus

L Barham, N Latimer and E Bramley-Harker (October 2005) Coronary Heart Disease and Diabetes – A Focus on Scotland, Pharma Pricing and Reimbursement, Vol 10, No 10, pp.304-305.

E Bramley-Harker, L Barham and N Latimer (September 2005) The Future Burden of CHD and Diabetes in Scotland: The Value of Health Care Innovation, NERA, London.

L Barham and E Bramley-Harker (September 2004) Diabetes and CHD – Challenges for Health Care Payers in the UK, Pharma Pricing and Reimbursement, Vol 9, No 9, pp.268-270.

E Bramley-Harker and L Barham (May 2004) The Human and Economic Value of Innovation and Opportunities for the NHS, NERA, London.

L Barham and E Bramley-Harker (May 2004) Comparing Physicians’ Earnings: Current Knowledge and Challenges: A Report for the Department of Health, NERA, London.

L Barham and E Bramley-Harker (Jan 2004) The MS Risk-Sharing Scheme – Eighteen Months On, Pharmaceutical Pricing and Reimbursement, Vol 9, No 1, pp. 8-9.

E Bramley-Harker, D Whitaker and L Barham, Taiwan Pharmaceutical Price Gap: A Report for PhRMA, (May 2003), NERA, London.

Social issues

J Dodgson, L Barham and S Maunder (2006) NERA Response to Blackpool, NERA, London

http://www.culture.gov.uk/Cap/eip/eip_docs/blackpool/post_info/NERAresponsetoBlackpoolCAP_201006.pdf

E Bramley-Harker, G Hughes, L Barham et al (2005) Economic Impact of a Casino in the Wembley Development Area, for Brent Policy and Regeneration Unit

http://www.longitude0.co.uk/against-the-casino/downloads/Brent-Economic-Impacts-Regional-Casino.pdf

C Penfold, G Hunter, R Campbell and L Barham (December 2004) Tackling Client Violence in Female Street Prostitution: Inter-Agency Working Between Outreach Agencies and the Police, Policing and Society, Vol. 14, No. 4. pp. 365 -379.

L Barham, E Bramley-Harker, M Hickman, M Hough, and P J Turnbull (2003) Sizing the Market for Powder Cocaine – Is a New Approach Needed? Howard Journal of Criminal Justice, Vol 42, No 4 pp 366-373.

J Dodgson, E Bramley-Harker, M Spackman, S Aslam and L Barham, Alcohol in London: A Cost Benefit Analysis: A Report for the Greater London Authority, (January 2003), NERA, London.

NERA (2003) “The London Labour Market: Case for London Technical Report 4”, for GLA Economics

http://www.london.gov.uk/mayor/economic_unit/case_for_london/labour_market_report_main.pdf

E Bramley-Harker, G Hughes, L Barham et al (2005) A Review of Visitors Indicators Used in Formula Spending Shares, for ODPM,

http://www.local.communities.gov.uk/finance/0607/swg0501/visitors%20final%20interim%20report.pdf

Dodgson, J, Spackman, M and Barham, L et al (April 2004) Evaluating the Processes and Impacts of Integrated Transport and the Cross-sector Benefits of Improved Accessibility: Phase1, Department for Transport, London http://www.dft.gov.uk/stellent/groups/dft_localtrans/documents/page/dft_localtrans_032545.pdf

Post

L Barham, J Dodgson, and S Maunder (March 2007) Managed Closure of Post Office Branches – Learning from the UK Experience, Postal Technology International

J Dodgson, L Barham, S Maunder, M Ng and S Carter (2007) Access to Postal Services, for Postcomm, London

http://www.psc.gov.uk/postcomm/live/news-and-events/news-releases/2007/greater-focus-needed-on-creating-a-sustainable-and-viable-post-office-network-for-the-future/2007_08_access_to_postal_services_report.pdf

J Dodgson, L Barham, S Maunder and S Carter (2006) The 2006 Business Customer Survey, for Postcomm, London

http://www.psc.gov.uk/postcomm/live/competition/business-customer-survey/Business_Customer_Survey_2006_revised.pdf

J Dodgson, L Barham and S Maunder (2006) Post Office Urban Reinvention – One Year On, for Postcomm, NERA, London

http://www.psc.gov.uk/postcomm/live/post-offices/research/NERA_Final_Report_URP_One_Year_On_080906.pdf

J Dodgson, L Barham and S Maunder (2005) Review of the Post Office Urban Reinvention Programme, for Postcomm, NERA, London

http://www.postcomm.gov.uk/post-offices/research/Published_URP_Report.pdf

J Dodgson, M Spackman, L Barham et al (June 2003) Cost-Benefit Analysis of Rural Post Office Branches : A Report to the Postal Services Commission, NERA, London.